NewAmsterdam Pharma Co N.V. — Form 8-K
Filed July 22, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
NewAmsterdam Pharma filed an 8-K on 2026-07-22 reporting Item 5.02 disclosures concerning departure of directors or officers, election of directors, appointment of officers, and compensatory arrangements. The filing document itself contains no specific names, dollar amounts, dates of departure/appointment, share counts, or compensation details—only metadata and XBRL structure tags. Substantive information is not visible in the text provided.
Why this rating
Filing signals routine personnel/compensation disclosure. Absence of concrete details prevents materiality assessment. No financial impact quantified relative to $1.3B market cap.
Extracted items
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.